Announcement

UCB and Huma partner to provide digital health solution to improve management of the rare disease, Myasthenia gravis

April 26, 2023
Announcement

UCB and Huma partner to provide digital health solution to improve management of the rare disease, Myasthenia gravis

April 26, 2023

This is some text inside of a div block.
mins read
  • Project aims to improve patient outcomes through better clinical management of disease exacerbations using self-reported data
  • Exciting opportunity to improve education and empowerment and for patients to be active participants in their own care
  • Huma’s EU MDR Class IIb regulated Software as Medical Device technology will advance proactive, predictive, personalised care for people with a rare disease
Speaker shot.

Speaker shot.

Speaker shot.

NEW YORK and LONDON, (APRIL. 26, 2023) - Huma Therapeutics (“Huma”), a leading global digital health company, and UCB, a global biopharmaceutical company, are partnering to offer a digital technology solution to help patients with the rare disease, Myasthenia gravis (MG), better understand and manage their condition with the support of their clinician. The digital platform is launching in Europe ahead of international expansion. 

The technology platform is founded on Huma’s EU MDR Class IIb regulated Software as a Medical Device (SaMD) - the only disease agnostic SaMD to receive this level of EU MDR regulatory classification to-date. It will provide patients with access to MG-specific, trusted educational materials, and the ability to report and track their symptoms over time using the MG-Activities of Daily Living Scale (MG-ADL)1. These data are shared with clinicians through a web-based dashboard to detect exacerbations in symptoms early and intervene where necessary. Identifying exacerbation triggers will support proactive clinical decision-making and should improve patient experience. Patients can download summary reports of their health data to discuss with their clinician to maximise in-person consultations.

“Our new classification of Class IIb level regulation means that we can work more collaboratively and in a shorter time frame with our pharma partners to launch solutions with predictive algorithms that can have a major impact for patients at the individual level, that’s why our approach is revolutionary.”

Dan Vahdat, CEO and Founder of Huma

Dan Vahdat, CEO and Founder of Huma, said: “There has been a huge growth in drug development for rare diseases and creating treatments for this population requires a greater degree of personalisation, which is exactly what our digital health platform provides. Our new classification of Class IIb level regulation means that we can work more collaboratively and in a shorter time frame with our pharma partners to launch solutions with predictive algorithms that can have a major impact for patients at the individual level, that’s why our approach is revolutionary. We’re excited to partner with UCB and be able to bring benefit to rare disease patients again, which is where we began when the company launched over a decade ago.”

The partnership is part of UCB’s approach to offer a patient-centred approach to transform the way care is delivered to rare disease populations in a meaningful, tangible, and real-world setting. 

Charl van Zyl, Executive Vice President Neurology & Head Of Europe/International Markets at UCB, said: “UCB is working to enable people with rare diseases to live the best life that they can. Symptoms of Myasthenia gravis can vary greatly and each person experiences the disease in a uniquely personal way. We believe that innovations in digital health solutions can offer the necessary personalised support, education, and resources for each patient.”

Colin Lake, Vice President, Head of Digital Care Transformation, Neurology, Head of Digital Rare Disease UCB, said: “This digital solution is an important first step in demonstrating UCB’s commitment to the rare disease community. We are beginning in Myasthenia gravis and we have the ambition to expand to other rare diseases. We’re delighted to work with Huma as we believe that partnerships are key to creating the best-in-class patient experience for patients across the rare disease community.”

This field is required
Email must be formatted correctly
This field is required
This field is required
This field is required

Huma is committed to respecting your privacy, we’ll always treat your personal details with the utmost care and will never sell them to other companies for marketing purposes. You can unsubscribe at any time. Review our Privacy Policy for further information.

Keep up to date on our current work and research with the latest marketing updates from Huma, including monthly news, events and communications on products and services.

By clicking submit below, you consent to allow Huma to store and process the personal information submitted above to provide you the content requested.

One of our team members will be in touch with you shortly.
Oops! Something went wrong while submitting the form.

About Huma

Huma Therapeutics is a global digital health technology company that advances digital-first care delivery and research to help people live longer, fuller lives.

Huma's award-winning modular platforms are used by more than 3,000 hospitals and clinics, with 1.8+ million active users in healthcare and 650,000+ participants across research. Huma's regulated Software as a Medical Device is the only disease agnostic platform to hold EU MDR Class IIb certification status. It powers:

  • Digital first care for health systems
  • companion apps to support patients through treatment and drug therapies
  • virtual clinical trials to accelerate research

Please visit www.huma.com and follow us on LinkedIn at Huma

About UCB 

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or the central nervous system. With approximately 8 700 people in approximately 40 countries, the company generated revenue of € 5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB).

Media contacts:

Contact (Huma):

Karen Birmingham PhD
Head of PR & Communications, Huma
karen.birmingham@huma.com

Contact (UCB):

Jim Baxter
Brand Communications, Rare Diseases
T+32.2.473.78.85.01
jim.baxter@ucb.com 

This field is required
This field is required
This field is required
This field is required
Thank you for your request.
You will receive an email from us shortly containing the file. Please check your inbox (and promotions tab or spam folder, if necessary) for the email.
Oops! Something went wrong while submitting the form

Contact us to discover more

Email must be formatted correctly
This field is required
This field is required
This field is required
This field is required
This field is required
Country/Region*
This field is required
I'm interested in

Huma is committed to respecting your privacy, and we’ll only use your personal details to provide information you have selected you’re interested in. Review our Privacy Policy for further information.

We’d love to send you our monthly newsletter about our latest work, research and events by email. We’ll always treat your personal details with the utmost care and will never sell them to other companies for marketing purposes.

You’re in control. You can, of course, withdraw your consent at any time. Review our Privacy Policy for further information.

One of our team members will be in touch with you shortly.
Oops! Something went wrong while submitting the form.

Making an impact

3000+

3000+ hospitals and clinics supported across Huma platforms to secure the most sustainable impact for patients1

×2

Our platform can almost double clinical capacity and reduce readmission rates by >30%3

27m+

Huma's digital-first health platforms support a network of 27m patients1

1m+

Over 1 million devices have been shipped in support of our projects and we know what it takes to deploy at scale1

Winner of the 2022 Prix Galien award for digital health, widely regarded as 'pharma's Nobel prize'4

Selected as one of 'The Most Important Healthcare Design of 2021' by Fast Company5

Winner of the 2022 Prix Galien award for digital health, widely regarded as 'pharma's Nobel prize'4

Winner of the 2022 Prix Galien award for digital health, widely regarded as 'pharma's Nobel prize'4

Sources:

  1. Talking, chewing, breathing, swallowing, impaired ability to brush teeth or comb hair, impaired ability to rise from a chair, double vision, eyelid droop.

Announcement

UCB and Huma partner to provide digital health solution to improve management of the rare disease, Myasthenia gravis

April 26, 2023
Announcement

UCB and Huma partner to provide digital health solution to improve management of the rare disease, Myasthenia gravis

April 26, 2023

Huma joins digital pioneers to advance health equity in care and research

Chief Executive Officer and Founder, Dan Vahdat, is returning to the annual World Economic Forum’s main conference where he will join a panel discussion devoted to improving care for non-communicable disease and tackling health equity. Accompanied by Chief Financial and Strategy Officer, Ingeborg Oie, Dan is looking forward to connecting with other attendees to explore how Huma’s digital health platform can make healthcare more equitable, and advances proactive, predictive care.

Huma joins digital pioneers to advance health equity in care and research

Date:Wednesday, January 18, 2023
Time:4:15 - 5:15 p.m. CET
Location:Ice Village, Eisbahnstrasse 5, Davos, Switzerland
Dan will join the Digital Health Action Alliance panel at Davos to discuss Turning the Tide in Non-Communicable Disease Care Through Digital Health and Community Connection. Huma has a long history of advancing the care of non-communicable diseases (NCDs) such as heart disease, cancer, diabetes and lung conditions. Huma’s innovative remote patient monitoring platform enables broad patient recruitment, reduces reliance on in-person clinic visits and increases health system efficiency.
*This session is open to registered Annual Meeting 2023 participants and Affiliate badge holders.

Huma is one of the first to sign the Zero Health Gaps Pledge

Huma is one of the first signatories to the Zero Health Gaps Pledge, the World Economic Forum’s Global Health Equity Network’s (GHEN) initiative. Huma supports GHEN’s ambition to build a future without disparities in health or wellbeing outcomes. Huma’s digital platform has been built on a deep clinical knowledge of complex patient needs and how people engage with technology and we are committed to ensuring our technology promotes health equity. We are proud to work with governments, hospital groups, universities, life science and technology companies to bring greater scale and impact and help all people live longer, fuller lives.

Huma at World Economic Forum

Global Innovators and Tech Pioneers
Dec 2022: Huma selected to join 100 innovative companies on a two-year journey as part of the World Economic Forum’s initiatives, activities and events, bringing their cutting-edge insight and fresh thinking to critical global discussions.
Learn more
Working Together, Restoring Trust
May 2022: With the aim to address economic, environmental, political, and social fault-lines exacerbated by the COVID-19 pandemic, Dan Vahdat speaks at WEF annual meeting about the importance of scientific collaboration.
Learn more
Accelerating innovation and breaking new ground
October 2022: Dan joined the WEF Biotech Future Forum 2022 to discuss how start-ups are breaking new ground in biotech and changing the way we interact with the world, but also how the sector can earn trust, scale successfully and spot the brightest innovations.
Learn more
Making connections at Davos
Jan 2019: Dan attended WEF as an unofficial attendee and spoke to CNBC about the importance of meeting in-person to make connections.
Learn more

Related Articles

See more
Article
AI is in our DNA
Explore how Huma has been developing AI to revolutionise healthcare, and request a meeting with us to find out more.
Learn more
Article
“It’s really gold dust” Why Huma is a big step forward for knee surgery
Discover how Huma is providing Smith+Nephew with real world evidence for robotic knee replacement surgery.
Learn more

Related Blogs

See more
Blog
Feeling depressed linked to short-term increase in bodyweight, study finds
Learn more
Blog
How Huma is transforming Health
Tim Broke-Smith, Huma's Vice President, Global Pharma Partnerships, considers how cutting edge technology can transform healthcare.
Learn more

Related Ebooks

See more
Ebook
Welcome to next-generation digital-first care and research
Deliver more personalised digital-first care and research with the first disease agnostic enterprise platform to achieve EU MDR Class IIb certification1.
Learn more
Ebook
What does FDA 510(k) Class II mean for Huma and our partners
Deliver more personalised digital-first care and research with our enterprise platform which now has FDA 510 (K) Class II clearance for any physician-specified condition.
Learn more

Related White Papers

See more
White Paper
Navigating the DCT transition
Learn how remote trial technology is changing the clinical trial landscape and key considerations when including DCT components in your study protocols.
Learn more
Announcement

UCB and Huma partner to provide digital health solution to improve management of the rare disease, Myasthenia gravis

April 26, 2023
Media contact
A headshot of Karen Birmingham PhD
Karen Birmingham PhD
Head of PR & Communications
karen.birmingham@huma.com
Announcement

UCB and Huma partner to provide digital health solution to improve management of the rare disease, Myasthenia gravis

April 26, 2023
Media contact
A headshot of Karen Birmingham PhD
Karen Birmingham PhD
Head of PR & Communications
karen.birmingham@huma.com

NEW YORK and LONDON, (APRIL. 26, 2023) - Huma Therapeutics (“Huma”), a leading global digital health company, and UCB, a global biopharmaceutical company, are partnering to offer a digital technology solution to help patients with the rare disease, Myasthenia gravis (MG), better understand and manage their condition with the support of their clinician. The digital platform is launching in Europe ahead of international expansion. 

The technology platform is founded on Huma’s EU MDR Class IIb regulated Software as a Medical Device (SaMD) - the only disease agnostic SaMD to receive this level of EU MDR regulatory classification to-date. It will provide patients with access to MG-specific, trusted educational materials, and the ability to report and track their symptoms over time using the MG-Activities of Daily Living Scale (MG-ADL)1. These data are shared with clinicians through a web-based dashboard to detect exacerbations in symptoms early and intervene where necessary. Identifying exacerbation triggers will support proactive clinical decision-making and should improve patient experience. Patients can download summary reports of their health data to discuss with their clinician to maximise in-person consultations.

asdasd

asda

asdsads

asda

asdsad

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
Download
Share this
COMPANY

About Huma

Huma began its journey in 2011, when the company was founded in London. Since then, Huma has grown to become a global healthcare company, spanning across multiple geographies and operating across four continents.

Learn more